About Quaker Partners Management
Quaker Partners Management is a venture capital firm founded in 2002. It is primarily based out of Philadelphia, United States. As of Mar 2021, Quaker Partners Management has invested in 33 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series E round of Rapid Micro Biosystems Overall, Quaker Partners Management portfolio has seen 5 IPOs and 20 acquisitions including key companies like NeuroStar, TELA Bio and Amicus Therapeutics. A lot of funds co-invest with Quaker Partners Management, with names like Birchmere Ventures sharing a substantial percentage of its portfolio. Quaker Partners Management has team of 3 people including 3 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 5 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Quaker Partners Management's List of Top Investments
Quaker Partners Management has a portfolio of 33 companies. Their most notable investments are in NuPathe and EKR Therapeutics.Their portfolio spans across United States, Ireland, Australia and 2 more locations. They have invested in Life Sciences, High Tech, HealthTech and 3 other sectors, across stages such as Series A, Series B and 5 more. Here is the list of top investments by Quaker Partners Management:1. NeuroStar
Provider of a non-drug non-invasive therapeutic devices for neurorehabilitation. It focuses on the therapeutic applications of the MRI-strength pulsed magnetic field for treating disorders of the central nervous system. The TMS Therapy is an FDA cleared device used for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
Key facts about NeuroStar
- Founded Year: 2003
- Location: Malvern (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $119M
- Employee Count: 211 as on May 31, 2026
- Investors: Quaker Partners Management, Industry Ventures and 14 Others
- Latest Funding Round: Conventional Debt, Mar 02, 2020, $*****
- Highlight: Public
2. TELA Bio
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction. It offers soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials.
Key facts about TELA Bio
- Founded Year: 2012
- Location: Malvern (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $104M
- Employee Count: 231 as on May 31, 2026
- Investors: Quaker Partners Management, Hercules Capital and 6 Others
- Latest Funding Round: Series B, Jul 10, 2019, $*****
- Highlight: Public
Developer of therapies for rare and orphan diseases. It has a pipeline of small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases. These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. Its drug pipeline includes migalastat, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, and SD-101 for the treatment of the rare genetic connective tissue disorder Epidermolysis Bullosa (EB).
Key facts about Amicus Therapeutics
- Founded Year: 2002
- Location: Philadelphia (United States)
- Annual Revenue: $10M - $50M as on Dec 31, 2017
- Stage: Acquired
- Total Funding till date: $91M
- Employee Count: 619 as on May 31, 2026
- Investors: HBM Healthcare Investments, Quaker Partners Management and 10 Others
- Latest Funding Round: Post IPO, Oct 02, 2023, $*****
- Highlight: Acquired
4. Insmed
Developer of small molecule inhibitors for rare lung diseases. Its lead candidate is Arikayce (liposomal amikacin for inhalation), a ribosomal 30S subunit inhibitor for nontuberculous mycobacteria (NTM) lung disease. It also has an earlier-stage clinical pipeline which includes INS1009, a nebulized prodrug formulation of treprostinil that claims to have potential in rare pulmonary disorders such as pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis (IPF) sarcoidosis, and severe refractory asthma.
Key facts about Insmed
- Founded Year: 1999
- Location: Bridgewater (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Employee Count: 1,710 as on May 31, 2026
- Investors: Foresite Capital, Quaker Partners Management and 13 Others
- Latest Funding Round: Grant (prize money), Apr 29, 2025, $*****
- Highlight: Public
Developer of biosystems for microbial contamination detection. The company offers the Growth Direct system that includes an automated imaging instrument that automatically counts microcolonies of bacteria or fungi, much earlier than traditional visual colony counting methods by measuring the autofluorescence emitted by microbial cells. The company provides on-site installation, instrument, validation services, regulatory compliance assistance, and others. Its solutions are used in environmental monitoring, and sterility and bioburden testing applications.
Key facts about Rapid Micro Biosystems
- Founded Year: 2006
- Location: Bedford (United Kingdom)
- Annual Revenue: $10M - $50M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $350M
- Employee Count: 208 as on May 31, 2026
- Investors: HTIF, T. Rowe Price and 22 Others
- Latest Funding Round: Series E, Mar 16, 2021, $*****
- Highlight: Public
Quaker Partners Management's Investments by Stage
Quaker Partners Management has made 5 investments in Series A stage with an average round size of $12.5M, 5 investments in Series B stage with an average round size of $16.6M and 3 investments in Series D stage with an average round size of $42.8M.Stage of entry | No. of Investments |
|---|---|
Series A | 5 |
Series B | 5 |
Series D | 3 |
Series C | 2 |
PE | 1 |
Others | 2 |
Note: We have considered here, only first round of investments
Quaker Partners Management's Investments by Sector
Quaker Partners Management has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, HealthTech, High Tech and Sustainability Tech. Notably, it has invested in 28 Tech companies, 22 Enterprise (B2B) companies, 6 Consumer (B2C) companies and at least 5 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 17 |
Enterprise Applications | 3 |
HealthTech | 3 |
High Tech | 2 |
Sustainability Tech | 2 |
Others | 2 |
Note: We have considered here, only first round of investments
Quaker Partners Management's Investments by Geography
Quaker Partners Management has made most investments in United States (16), followed by Ireland where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 16 |
Ireland | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Quaker Partners Management's recent investments
Quaker Partners Management has not made any investment in 2026 so far.Here are the most recent investments by Quaker Partners Management:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Mar 16, 2021 | United Kingdom | Series E | 2345 | [+9] | |
Jun 04, 2019 | United States | Series B | 6752 | [+2] | |
May 29, 2019 | United States | Series D | 6182 | [+2] | |
Apr 16, 2018 | United States | Series C | 6178 | ||
Jan 03, 2017 | United States | Series B | 8787 |
IPOs and Publicly Listed companies in Quaker Partners Management's Portfolio
5 of Quaker Partners Management's portfolio companies have become public. Rapid Micro Biosystems got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2021 at marketcap of $800M and TELA Bio got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $15.1M.Here are Quaker Partners Management's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 15, 2021 | Jul 08, 2009 | Series A | 3253 | |
Nov 08, 2019 | - | - | 4503 | |
Jun 28, 2018 | - | - | 9959 | |
Jun 01, 2000 | - | - | 5215 | |
- | - | - | 5742 |
Acquired companies in Quaker Partners Management's Portfolio
20 companies from Quaker Partners Management's portfolio have been acquired. The most recent acquisition was Amicus Therapeutics in Dec 2025 by BioMarin Pharmaceutical for $*****.Here are Quaker Partners Management's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 19, 2025 | Sep 08, 2005 | Series C | 1692 | |
Aug 07, 2025 | - | - | 9352 | |
Jan 06, 2024 | Nov 11, 2008 | PE | 1940 | |
Dec 12, 2022 | - | - | 8896 | |
May 04, 2022 | - | - | 2792 |
_1583130766305.png?devicePixelRatio=2&height=20&width=20){kind=logo}
Team profile of Quaker Partners Management
Quaker Partners Management has a team of 3 members including 3 Partners located in United States. Quaker Partners Management's team does not sit on the board of any company as of now.Here is a list of all team members in Quaker Partners Management:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Bryn Mawr | - | - | |
Partner | Philadelphia | - | ||
Partner | Pennsylvania Furnace | - | - |
Co-investors of Quaker Partners Management
Over the past 24 years, 99 investors have co-invested in Quaker Partners Management's portfolio companies. This includes funds and angels.
- Invested before Quaker Partners Management: New Enterprise Associates, Canaan and 16 others have invested in rounds before Quaker Partners Management. There are 2 companies where New Enterprise Associates has invested before Quaker Partners Management and 1 company where Canaan has invested before Quaker Partners Management.
- Top Co-investors of Quaker Partners Management: 40 investors entered a company along with Quaker Partners Management. These include investors like Birchmere Ventures (3 companies).
- Invested after Quaker Partners Management: A total of 41 investors have invested in Quaker Partners Management's portfolio after their investments. Top Investors include Vensana Capital (2 companies), Square 1 Bank (2 companies) and Oxford Finance (2 companies).
Recent News related to Quaker Partners Management
•
•
•
•
•
Intact Vascular Closes Series C Financing at USD 20 MillionMedical Buyer•Apr 18, 2018•Agilent, Intact Vascular, New Enterprise Associates, HIG BioHealth Partners and 1 other
•
Intact Vascular raises $10m, looks to raise $12m moreMassDevice•Apr 14, 2018•Intact Vascular, New Enterprise Associates, HIG BioHealth Partners, Quaker Partners Management and 1 other
•
•
Rapid Micro Biosystems Secures $25 Million in Series C Equity FinancingGlobeNewswire•Apr 29, 2015•Rapid Micro Biosystems, Shenzhen Hepalink Pharmaceutical, Longitude Capital, and 3 others
•
Tarsa Therapeutics Raises $7M in Second Tranche of Series B Round |FinSMEsFinSMEs•May 29, 2014•Tarsa Therapeutics, Foresite Capital, Quaker Partners Management, Novo Holdings and 1 other
•
